Catalyst Event
Merck and Co Inc (MRK) · Other
From KEDI U.S. Dividend100 90% Participation + Daily Options Premium Index (KUSDV100P)
5/29/2026, 12:00:00 AM
The FDA granted Breakthrough Therapy Designation for the investigational KRAS G12C inhibitor calderasib (MK-1084) on May 29, 2026.
Korean Translation
2026년 5월 29일 미국 FDA로부터 KRAS G12C 억제제 후보물질 칼데라십(MK-1084)에 대한 혁신 치료제 지정을 획득함.
Related Recent Events
Target Corp (TGT) · Earnings Release
Target's Q2 2026 earnings release is set for August 19, 2026; low importance is estimated as the date announcement itself typically has a market impact of less than 5%, scheduled.
8/19/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Other
The U.S. FDA set a PDUFA target action date for iberdomide on 2026-08-17; importance is Low as the setting of a PDUFA date is a procedural event with minor price impact.
8/17/2026, 12:00:00 AM
Chevron Corp (CVX) · Earnings Release
Q2 2026 earnings release is scheduled for August 7, 2026; analysts forecast a significant increase in earnings due to higher oil prices and full integration of Hess assets. Market impact is estimated at Medium (5%) as earnings are a primary driver of stock volatility, scheduled.
8/7/2026, 12:00:00 AM
EOG Resources Inc. (EOG) · Earnings Release
Q2 2026 earnings release is scheduled.
8/6/2026, 12:00:00 AM
Cabot Corp (CBT) · Earnings Release
Q3 2026 earnings release and conference call scheduled.
8/3/2026, 12:00:00 AM
Exxon Mobil Corp (XOM) · Earnings Release
Q2 2026 earnings release is scheduled.
7/31/2026, 12:00:00 AM